End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?

Evgeny Degtyareva Novartis Pharma, Basel, SwitzerlandCorrespondence[email protected]

https://orcid.org/0009-0006-6894-9847

Natacha Bolañosb Lymphoma Coalition, Madrid, Spain

Joshua D Brodyc Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Aby Buchbinderd Novartis Pharmaceuticals, East Hanover, NJ, USA

Marc Buysee International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium;f Interuniversity Institute for Biostatistics & Statistical Bioinformatics (I-BioStat), Hasselt University, Diepenbeek, Belgium

Miriam Fuchsa Novartis Pharma, Basel, Switzerland

Susan Halabig Duke Clinical Research Institute, Durham, North Carolina, USA;h Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA

Robert Hemmingsi CONSILIUM Salmonson & Hemmings, Woking, UK

Aisha Masoodd Novartis Pharmaceuticals, East Hanover, NJ, USA

Simon Newsomea Novartis Pharma, Basel, Switzerland

Claire Saxtonj Cancer Support Community, Washington, DC, USA

Lorna Warwickk Lymphoma Coalition, Management, Mississauga ON, Canada

Nigel A Yatemana Novartis Pharma, Basel, Switzerland

Emmanuel Zubera Novartis Pharma, Basel, Switzerland

show all

End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date